Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ain Shams University
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Breast cancer patients aged 18 years old or more
Female patients
Histologically proven invasive breast cancer
Histologically proven HR-positive and HER2-negative breast cancer
Metastatic breast cancer (Stage 4 according to AJCC 8th edition 2017)
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 3.
Adequate hematological and organs function
Patients receiving CDK 4/6 inhibitor combined with endocrine therapy(Aromatase inhibitors , GnRH agonists, fulvastrent). as a first or second line treatment
You may not be if
\- Male breast cancer patients
Patients in, visceral crisis (defined as : severe organ dysfunction, as assessed by signs and symptoms, laboratory studies and rapid progression of disease ) that are at risk of life threatening complication in the short term.
Prior treatment with any CDK 4/6 inhibitor.
History of any other cancer , unless in complete remission with no therapy for a minimum of 3 years.
Have active bacterial or fungal infection, or detectable viral infection.
Clareo Health | Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy
